Antifungal resistance: current trends and future strategies to combat

References

• VallabhaneniSClevelandAAFarleyMMEpidemiology and risk factors for echinocandin nonsusceptible Candida glabrata bloodstream infections: data from a large multisite population-based candidemia surveillance program, 2008–2014Open Forum Infect Dis201524ofv16326677456
   PubMedGoogle Scholar
• VerweijPEChowdharyAMelchersWJMeisJFAzole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles?Clin Infect Dis201662336236826486705
   PubMed Web of Science ®Google Scholar
• Rivero-MenendezOAlastruey-IzquierdoAMelladoECuenca-EstrellaMTriazole resistance in Aspergillus spp: a worldwide problem?J Fungi20162321
   Web of Science ®Google Scholar
• LacknerMHagenFMeisJFSusceptibility and diversity in the therapy-refractory genus scedosporiumAntimicrob Agents Chemother201458105877588525070092
   PubMed Web of Science ®Google Scholar
• LacknerMde HoogGSYangLProposed nomenclature for Pseudallescheria, Scedosporium and related generaFungal Divers2014671110
   Web of Science ®Google Scholar
• WalshTJGrollAHiemenzJFlemingRRoilidesEAnaissieEInfections due to emerging and uncommon medically important fungal pathogensClin Microbiol Infect200410Suppl 1486614748802
   PubMed Web of Science ®Google Scholar
• LockhartSREtienneKAVallabhaneniSSimultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyzesClin Infect Dis201764213414027988485
   PubMed Web of Science ®Google Scholar
• PfallerMADiekemaDJGibbsDLResults from the ARTEMIS DISK global antifungal surveillance study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusionJ Clin Microbiol20104841366137720164282
   PubMed Web of Science ®Google Scholar
• PfallerMAMesserSAMoetGJJonesRNCastanheiraMCandida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in intensive care unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008–2009)Int J Antimicrob Agents2011381656921514797
   PubMed Web of Science ®Google Scholar
• YaparNEpidemiology and risk factors for invasive candidiasisTher Clin Risk Manag2014109510524611015
   PubMed Web of Science ®Google Scholar
• WHOAntimicrobial Resistance: Global Report on Surveillance2014 Available from: http://www.who.int/drugresistance/documents/surveillancereport/en/Accessed June 21, 2017
   Google Scholar
• WhiteTCMarrKABowdenRAClinical, cellular, and molecular factors that contribute to antifungal drug resistanceClin Microbiol Rev19981123824029564569
   PubMed Web of Science ®Google Scholar
• SanglardDEmerging threats in antifungal-resistant fungal pathogensFront Med (Lausanne)201631127014694
   PubMed Web of Science ®Google Scholar
• OberoiJKWattalCGoelNRaveendranRDattaSPrasadKNon-albicans Candida species in blood stream infections in a tertiary care hospital at New Delhi, IndiaIndian J Med Res20121366997100323391796
   PubMed Web of Science ®Google Scholar
• BeydaNDJohnJKilicAAlamMJLascoTMGareyKWFKS mutant Candida glabrata: risk factors and outcomes in patients with candidemiaClin Infect Dis201459681982524879785
   PubMed Web of Science ®Google Scholar
• AlexanderBDJohnsonMDPfeifferCDIncreasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrationsClin Infect Dis201356121724173223487382
   PubMed Web of Science ®Google Scholar
• ChakrabartiASoodPRudramurthySMIncidence, characteristics and outcome of ICU-acquired candidemia in IndiaIntensive Care Med201541228529525510301
   PubMed Web of Science ®Google Scholar
• AdhikaryRJoshiSSpecies distribution and anti-fungal susceptibility of Candidaemia at a multi super-specialty center in Southern IndiaIndian J Med Microbiol201129330931121860117
   PubMed Web of Science ®Google Scholar
• PfallerMACastanheiraMMesserSAJonesRNIn vitro antifungal susceptibilities of isolates of Candida spp. and Aspergillus spp. from China to nine systemically active antifungal agents: data from the SENTRY antifungal surveillance program, 2010 through 2012Mycoses201558420921425727853
   PubMed Web of Science ®Google Scholar
• GuoFYangYKangYInvasive candidiasis in intensive care units in China: a multicentre prospective observational studyJ Antimicrob Chemother20136871660166823543609
   PubMed Web of Science ®Google Scholar
• XiaoMFanXChenSCAntifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillanceJ Antimicrob Chemother201570380281025473027
   PubMed Web of Science ®Google Scholar
• LiaoXQiuHLiRRisk factors for fluconazole-resistant invasive candidiasis in intensive care unit patients: an analysis from the China Survey of Candidiasis studyJ Crit Care2015304862.e1e5
   Web of Science ®Google Scholar
• PappasPGKauffmanCAAndesDRClinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of AmericaClin Infect Dis2016624e1e5026679628
   PubMed Web of Science ®Google Scholar
• MesserSADiekemaDJBoykenLTendolkarSHollisRJPfallerMAActivities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida sppJ Clin Microbiol200644232432616455878
   PubMed Web of Science ®Google Scholar
• ParkSKellyRKahnJNSpecific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolatesAntimicrob Agents Chemother20054983264327316048935
   PubMed Web of Science ®Google Scholar
• Garcia-EffronGKatiyarSKParkSEdlindTDPerlinDSA naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibilityAntimicrob Agents Chemother20085272305231218443110
   PubMed Web of Science ®Google Scholar
• ThompsonGRWiederholdNPVallorACVillarealNCLewisJSPattersonTFDevelopment of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infectionAntimicrob Agents Chemother200852103783378518676885
   PubMed Web of Science ®Google Scholar
• ArendrupMCPerlinDSEchinocandin resistance: an emerging clinical problem?Curr Opin Infect Dis201427648449225304391
   PubMed Web of Science ®Google Scholar
• MalaniAHmoudJChiuLCarverPLBielaczycAKauffmanCACandida glabrata fungemia: experience in a tertiary care centerClin Infect Dis200541797598116142662
   PubMed Web of Science ®Google Scholar
• ShieldsRKNguyenMHPressEGUpdikeCLClancyCJAnidulafungin and micafungin MIC breakpoints are superior to that of caspofungin for identifying FKS mutant Candida glabrata strains and Echinocandin resistanceAntimicrob Agents Chemother201357126361636524060873
   PubMed Web of Science ®Google Scholar
• ShieldsRKNguyenMHPressEGThe presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrataAntimicrob Agents Chemother20125694862486922751546
   PubMed Web of Science ®Google Scholar
• Garcia-EffronGLeeSParkSClearyJDPerlinDSEffect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpointAntimicrob Agents Chemother20095393690369919546367
   PubMed Web of Science ®Google Scholar
• ArendrupMCPerlinDSJensenRHHowardSJGoodwinJHopeWDifferential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutationsAntimicrob Agents Chemother20125652435244222354305
   PubMed Web of Science ®Google Scholar
• PfallerMACastanheiraMLockhartSRAhlquistAMMesserSAJonesRNFrequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrataJ Clin Microbiol20125041199120322278842
   PubMed Web of Science ®Google Scholar
• HealeyKRZhaoYPerezWBPrevalent mutator genotype identified in fungal pathogen Candida glabrata promotes multi-drug resistanceNat Commun201671112827020939
   PubMed Web of Science ®Google Scholar
• ChowdharyASharmaCMeisJFCandida auris: a rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globallyPLoS Pathog2017135e100629028542486
   PubMed Web of Science ®Google Scholar
• KathuriaSSinghPKSharmaCMultidrug-resistant Candida auris misidentified as Candida haemulonii: characterization by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry and DNA sequencing and its antifungal susceptibility profile variability by Vitek 2, CLSI Broth Microdilution, and Etest MethodJ Clin Microbiol20155361823183025809970
   PubMed Web of Science ®Google Scholar
• SharmaCKumarNPandeyRMeisJFChowdharyAWhole genome sequencing of emerging multidrug resistant Candida auris isolates in India demonstrates low genetic variationNew Microbes New Infect201613778227617098
   PubMedGoogle Scholar
• BueidAHowardSJMooreCBAzole antifungal resistance in Aspergillus fumigatus: 2008 and 2009J Antimicrob Chemother201065102116211820729241
   PubMed Web of Science ®Google Scholar
• HowardSJCerarDAndersonMJFrequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failureEmerg Infect Dis20091571068107619624922
   PubMed Web of Science ®Google Scholar
• ChowdharyASharmaCKathuriaSHagenFMeisJFAzole-resistant Aspergillus fumigatus with the environmental TR46/Y121F/T289A mutation in IndiaJ Antimicrob Chemother201469255555724084639
   PubMed Web of Science ®Google Scholar
• ChowdharyASharmaCvan den BoomMMulti-azole-resistant Aspergillus fumigatus in the environment in TanzaniaJ Antimicrob Chemother201469112979298325006238
   PubMed Web of Science ®Google Scholar
• VerweijPEMelladoEMelchersWJMultiple-triazole-resistant aspergillosisN Engl J Med20073561414811483
   PubMed Web of Science ®Google Scholar
• van der LindenJWCampsSMKampingaGAAspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domicilesClin Infect Dis201357451352023667263
   PubMed Web of Science ®Google Scholar
• LockhartSRFradeJPEtienneKAPfallerMADiekemaDJBalajeeSAAzole resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A geneAntimicrobl Agents Chemother201155944654468
   PubMed Web of Science ®Google Scholar
• SneldersEHuis In ‘t VeldRARijsAJKemaGHMelchersWJVerweijPEPossible environmental origin of resistance of Aspergillus fumigatus to medical triazolesAppl Environ Microbiol200975124053405719376899
   PubMed Web of Science ®Google Scholar
• SuguiJAPetersonSWFigatAGenetic relatedness versus biological compatibility between Aspergillus fumigatus and related speciesJ Clin Microbiol201452103707372125100816
   PubMed Web of Science ®Google Scholar
• BalajeeSAGribskovJBrandtMItoJFothergillAMarrKAMistaken identity: Neosartorya pseudofischeri and its anamorph masquerading as Aspergillus fumigatusJ Clin Microbiol200543125996599916333088
   PubMed Web of Science ®Google Scholar
• GhebremedhinBBluemelANeumannKHKoenigBKoenigWPeritonitis due to Neosartorya pseudofischeri in an elderly patient undergoing peritoneal dialysis successfully treated with voriconazoleJ Med Microbiol200958Pt 567868219369533
   PubMed Web of Science ®Google Scholar
• VargaJHoubrakenJVan Der LeeHAVerweijPESamsonRAAspergillus calidoustus sp. nov., causative agent of human infections previously assigned to Aspergillus ustusEukaryot Cell20087463063818281596
   PubMedGoogle Scholar
• BalajeeSAKanoRBaddleyJWMolecular identification of Aspergillus species collected for the Transplant-Associated Infection Surveillance NetworkJ Clin Microbiol200947103138314119675215
   PubMed Web of Science ®Google Scholar
• Alastruey-IzquierdoAMelladoEPelaezTPopulation-based survey of filamentous fungi and antifungal resistance in Spain (FILPOP Study)Antimicrob Agents Chemother20135773380338723669377
   PubMed Web of Science ®Google Scholar
• BalajeeSAHoubrakenJVerweijPEAspergillus species identification in the clinical settingStud Mycol200759394618490954
   PubMed Web of Science ®Google Scholar
• CornelyOAMaertensJBresnikMLiposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)Clin Infect Dis200744101289129717443465
   PubMed Web of Science ®Google Scholar
• PattersonTFThompsonGR3rdDenningDWPractice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of AmericaClin Infect Dis2016634e1e6027365388
   PubMed Web of Science ®Google Scholar
• JohnsonLSShieldsRKClancyCJEpidemiology, clinical manifestations, and outcomes of Scedosporium infections among solid organ transplant recipientsTranspl Infect Dis201416457858724962102
   PubMed Web of Science ®Google Scholar
• HusainSMunozPForrestGInfections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcomeClin Infect Dis2005401899915614697
   PubMed Web of Science ®Google Scholar
• LamarisGAChamilosGLewisRESafdarARaadIIKontoyiannisDPScedosporium infection in a tertiary care cancer center: a review of 25 cases from 1989–2006Clin Infect Dis200643121580158417109292
   PubMed Web of Science ®Google Scholar
• NucciMEmerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipientsCurr Opin Infect Dis200316660761214624113
   PubMed Web of Science ®Google Scholar
• DoligalskiCTBenedictKClevelandAAEpidemiology of invasive mold infections in lung transplant recipientsAm J Transplant20141461328133324726020
   PubMed Web of Science ®Google Scholar
• CortezKJRoilidesEQuiroz-TellesFInfections caused by Scedosporium sppClin Microbiol Rev200821115719718202441
   PubMed Web of Science ®Google Scholar
• LewisREWiederholdNPKlepserMEIn vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium sppAntimicrob Agents Chemother200549394595115728887
   PubMed Web of Science ®Google Scholar
• GuarroJKantarciogluASHorreRScedosporium apiospermum: changing clinical spectrum of a therapy-refractory opportunistMed Mycol200644429532716772225
   PubMed Web of Science ®Google Scholar
• KessonAMBellemoreMCO’MaraTJEllisDHSorrellTCScedosporium prolificans osteomyelitis in an immunocompetent child treated with a novel agent, hexadecylphospocholine (miltefosine), in combination with terbinafine and voriconazole: a case reportClin Infect Dis20094891257126119320594
   PubMed Web of Science ®Google Scholar
• BiswasCSorrellTCDjordjevicJTZuoXJolliffeKAChenSCIn vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogensJ Antimicrob Chemother201368122842284623861311
   PubMed Web of Science ®Google Scholar
• NucciMMarrKAQueiroz-TellesFFusarium infection in hematopoietic stem cell transplant recipientsClin Infect Dis20043891237124215127334
   PubMed Web of Science ®Google Scholar
• NucciMMarrKAVehreschildMJImprovement in the outcome of invasive fusariosis in the last decadeClin Microbiol Infect201420658058524118322
   PubMed Web of Science ®Google Scholar
• O’DonnellKSarverBABrandtMPhylogenetic diversity and microsphere array-based genotyping of human pathogenic Fusaria, including isolates from the multistate contact lens-associated U.S. keratitis outbreaks of 2005 and 2006J Clin Microbiol20074572235224817507522
   PubMed Web of Science ®Google Scholar
• HoekstraWJGarveyEPMooreWRRaffertySWYatesCMSchotzingerRJDesign and optimization of highly-selective fungal CYP51 inhibitorsBioorg Med Chem Lett201424153455345824948565
   PubMed Web of Science ®Google Scholar
• WarrilowAGHullCMParkerJEThe clinical candidate VT-1161 is a highly potent inhibitor of Candida albicans CYP51 but fails to bind the human enzymeAntimicrob Agents Chemother201458127121712725224009
   PubMed Web of Science ®Google Scholar
• WarrilowAGParkerJEPriceCLThe Investigational Drug VT-1129 is a highly potent inhibitor of Cryptococcus species CYP51 but only weakly inhibits the human enzymeAntimicrob Agents Chemother20166084530453827161631
   PubMed Web of Science ®Google Scholar
• ShubitzLFTrinhHTGalgianiJNEvaluation of VT-1161 for treatment of coccidioidomycosis in murine infection modelsAntimicrob Agents Chemother201559127249725426369964
   PubMed Web of Science ®Google Scholar
• FothergillAWWiederholdNPHoekstraWJThe fungal Cyp51 inhibitors VT-1129 and VT-1161 maintain in vitro activity against Candida albicans isolates with reduced antifungal susceptibility51st Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 17–20, 2011Chicago, IL
   Google Scholar
• LongLIshamNGhannoumMAHigh in vitro potency of the clinical investigational agent VT-1161 against clinical isolates of Candida spp25th European Congress of Clinical Microbiology and Infectious DiseasesApril 25–28, 2015Copenhagen, Denmark
   Google Scholar
• LockhartSRFothergillAWIqbalNThe investigational fungal Cyp51 inhibitor VT-1129 demonstrates potent n vitro activity against Cryptococcus neoformans and Cryptococcus gattiiAntimicrob Agents Chemother20166042528253126787697
   PubMed Web of Science ®Google Scholar
• GarveyEPHoekstraWJSchotzingerRJSobelJDLillyEAFidelPLJrEfficacy of the clinical agent VT-1161 against fluconazole-sensitive and -resistant Candida albicans in a murine model of vaginal candidiasisAntimicrob Agents Chemother20155995567557326124165
   PubMed Web of Science ®Google Scholar
• NajvarLKWiederholdNPGarveyEPEfficacy of the novel Fungal Cyp51 inhibitor VT-1161 against invasive candidiasis caused by resistant Candida albicans18th International Congress of the International Society of Human and Animal MycosesJune 11–15, 2012Berlin, Germany
   Google Scholar
• WiederholdNPNajvarLKGarveyEPEfficacy of the novel fungal Cyp51 inhibitors VT-1161 and VT-1411 against invasive candidiasis caused by Candida albicans and Candida glabrata11th American Society of Microbiology Conference on Candida and CandidiasisMarch 29 – April 2, 2012San Francisco, CA
   Google Scholar
• WiederholdNPTranHPattersonHPYatesCMSchotzingerRJGarveyEPThe Novel Fungal Cyp51 Inhibitor VT-1598 Demonstrates Potent In vitro Activity against Endemic Fungi, Aspergillus, and RhizopusASM MicrobeJune 1–5, 2017New Orleans, LA
   Google Scholar
• HargroveTYGarveyEPHoekstraWJCrystal structure of the new investigational drug candidate VT-1598 in complex with Aspergillus fumigatus sterol 14alpha-demethylase provides insights into its broad-spectrum antifungal activityAntimicrob Agents Chemother2017617e005701728461309
   PubMed Web of Science ®Google Scholar
• WiederholdNPTranHPattersonHPYatesCMSchotzingerRJGarveyEPThe Novel Fungal Cyp51 Inhibitor VT-1598 Demonstrates Potent In vitro Activity against Candida and Cryptococcus SpeciesASM MicrobeJune 1–5, 2017New Orleans, LA
   Google Scholar
• BerkowELLeNPetersonJIn vitro Activity of a Novel CYP51 Inhibitor, VT-1598, against Clinical Isolates of Candida aurisASM MicrobeJune 1–5, 2017New Orleans, LA
   Google Scholar
• JamesKKrishnanRSmithSLaudemanCPolowyKVaidyaABiafungin (CD101), a novel echinocandi, displays a long half-life in the chimpanzee, suggesting a once-weekly IV dosing option (abstr A-694)54th Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 5–9, 2014Washington, DC
   Google Scholar
• SandisonTOngVLeeJThyeDSafety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adultsAntimicrob Agents Chemother2017612e016271627919901
   PubMed Web of Science ®Google Scholar
• PfallerMAMesserSARhombergPRJonesRNCastanheiraMActivity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolatesJ Antimicrob Chemother201671102868287327287236
   PubMed Web of Science ®Google Scholar
• LockeJBAlmaguerALZuillDEBartizalKCharacterization of in vitro resistance development to the novel echinocandin CD101 in Candida speciesAntimicrob Agents Chemother201660106100610727480852
   PubMed Web of Science ®Google Scholar
• OngVHoughGSchlosserMPreclinical evaluation of the stability, safety and efficacy of CD101, a novel echinocandinAntimicrob Agents Chemother201660116872687927620474
   PubMed Web of Science ®Google Scholar
• ZhaoYPerezWBJimenez-OrtigosaCCD101: a novel longacting echinocandinCell Microbiol20161891308131627354115
   PubMed Web of Science ®Google Scholar
• GhannoumMLarkinELongLSusceptibilty of recent Candida auris isolates to the novel echinocandin CD101 and comparator antifungal agents27th European Congress on Clinical Microbiology and Infectious DiseasesApril 22–25, 2017Vienna, Austria
   Google Scholar
• PfallerMAMesserSAMotylMRJonesRNCastanheiraMActivity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST)J Antimicrob Chemother201368485886323190764
   PubMed Web of Science ®Google Scholar
• LepakAJMarchilloKAndesDRPharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis modelAntimicrob Agents Chemother20155921265127225512406
   PubMed Web of Science ®Google Scholar
• LarkinEHagerCChandraJThe emerging pathogen Candida auris: growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formationAntimicrob Agents Chemother2017615e023961628223375
   PubMed Web of Science ®Google Scholar
• BerkowELAnguloDLockhartSRIn vitro activity of a novel glucan synthase inhibitor, SCY-078, against clinical isolates of Candida aurisAntimicrob Agents Chemother2017617e004351728483955
   PubMed Web of Science ®Google Scholar
• LamothFAlexanderBDAntifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolatesAntimicrob Agents Chemother20155974308431125896696
   PubMed Web of Science ®Google Scholar
• OliverJDSibleyGEBeckmannNF901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenaseProc Natl Acad Sci U S A2016113451280912814
   PubMed Web of Science ®Google Scholar
• FothergillAWWiederholdNPSibleyGSpectrum of activity of F901318, the first agent from the newly discovered orotomide class of antifungals (abstr. F-756)Paper presented at: ICAAC/ICC 20152015San Diego, CA
   Google Scholar
• WiederholdNPLawDBirchMDihydroorotate dehydrogenase inhibitor F901318 has potent in vitro activity against Scedosporium species and Lomentospora prolificansJ Antimicrob Chemother Epub2017315
   Web of Science ®Google Scholar
• BuilJBRijsAJMMMeisJFMActivity of 901318 against azole-resistant and difficult-to-treat Aspergillus species (abstr. 1605)26th European Congress of Clinical Microbiology and Infectious DiseasesApril 9–12, 2016Amsterdam, the Netherlands
   Google Scholar
• ChaffinWLCandida albicans cell wall proteinsMicrobiol Mol Biol2008723495544
   PubMed Web of Science ®Google Scholar
• MiyazakiMHoriiTHataKIn vitro activity of E1210, a novel antifungal, against clinically important yeasts and moldsAntimicrob Agents Chemother201155104652465821825291
   PubMed Web of Science ®Google Scholar
• PfallerMADuncansonFMesserSAMoetGJJonesRNCastanheiraMIn vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methodsAntimicrob Agents Chemother201155115155515821844312
   PubMed Web of Science ®Google Scholar
• PfallerMAHataKJonesRNMesserSAMoetGJCastanheiraMIn vitro activity of a novel broad-spectrum antifungal, E1210, tested against Candida spp. as determined by CLSI broth microdilution methodDiagn Microbiol Infect Dis201171216717021696907
   PubMed Web of Science ®Google Scholar
• CastanheiraMDuncansonFPDiekemaDJGuarroJJonesRNPfallerMAActivities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methodsAntimicrob Agents Chemother201256135235722083469
   PubMed Web of Science ®Google Scholar
• WiederholdNPNajvarLKFothergillAWThe investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicansAntimicrob Agents Chemother201559169069225331706
   PubMed Web of Science ®Google Scholar
• HataKHoriiTMiyazakiMEfficacy of oral E1210, a new broad-spectrum antifungal with a novel mechanism of action, in murine models of candidiasis, aspergillosis, and fusariosisAntimicrob Agents Chemother201155104543455121788462
   PubMed Web of Science ®Google Scholar
• MitsuyamaJNomuraNHashimotoKIn vitro and in vivo antifungal activities of T-2307, a novel arylamidineAntimicrob Agents Chemother20085241318132418227186
   PubMed Web of Science ®Google Scholar
• ShibataTTakahashiTYamadaET-2307 causes collapse of mitochondrial membrane potential in yeastAntimicrob Agents Chemother201256115892589722948882
   PubMed Web of Science ®Google Scholar
• NishikawaHYamadaEShibataTUptake of T-2307, a novel arylamidine, in Candida albicansJ Antimicrob Chemother20106581681168720513704
   PubMed Web of Science ®Google Scholar
• WiederholdNPNajvarLKFothergillAWThe novel arylamidine T-2307 maintains in vitro and in vivo activity against echinocandin-resistant Candida albicansAntimicrob Agents Chemother20155921341134325451054
   PubMed Web of Science ®Google Scholar
• WiederholdNPNajvarLKFothergillAWThe novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant Candida glabrataJ Antimicrob Chemother201671369269526620102
   PubMed Web of Science ®Google Scholar
• NakamuraIOhsumiKYoshimatsuKASP2397: a novel natural prodcut with potent fungicidal activity against Aspergillus spp – a new mode of action and in vitro activity (abstr F-1590)54th Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 5–9, 2014Washington, DC
   Google Scholar
• NakamuraIYoshimuraSMasakiTASP2397: a novel antifungal agent produced by Acremonium persicinum MF-347833J Antibiot (Tokyo)2016717
   Google Scholar
• NakamuraIKanasakiRYoshikawaKDiscovery of a new antifungal agent ASP2397 using a silkworm model of Aspergillus fumigatus infectionJ Antibiot (Tokyo)2016701414427577982
   PubMed Web of Science ®Google Scholar
• NakamuraINakaiTMatsumotoSASP2397: a novel natural product with potent fungicidal activity against Aspergillus spp – In vivo activity against A fumigatus54th Interscience Conference on Antimicrobial Agents and ChemotherapySeptember 5–9, 2014Washington, DC
   Google Scholar
• WiederholdNPNajvarLKJaramilloRThe Novel Antifungal VL-2397 Demonstrates Efficacy in an In vivo Model of Invasive Candidiasis caused by Wild-Type and Multi-Drug Resistant Candida glabrataASM MicrobeJune 1–5, 2017New Orleans, LA
   Google Scholar
• MammenMPArmasDRSmithLRPhase 1 Safety and Pharmacokinetic Study of VL-2397, a Novel Antifungal AgentASM MicrobeJune 1–5, 2017New Orleans, LA
   Google Scholar